Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease

BMC Gastroenterology

Martin W Laass⁷  Karsten Conrad⁶  Alastair Forbes¹  Peter Malfertheiner³  Ulrike von Arnim³  Polychronis Pavlidis⁵  Thomas Wex³  Dirk Reinhold²  Dirk Roggenbuck⁴  Dimitrios P Bogdanos⁵ 

[1] Department of Gastroenterology and Clinical Nutrition, University College Hospital, London, UK;Institute of Molecular and Clinical Immunology, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Leipziger Str. 44, Germany;Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Magdeburg, 39120, Magdeburg, Leipziger Str. 44, Germany;GA Generic Assays GmbH, 15827, Dahlewitz, Berlin, L.-Erhard-Ring 3, Germany;Division of Transplantation Immunology and Mucosal Biology, King’s College London School of Medicine at King’s College Hospital, Denmark Hill Campus, Bessemer Road, London SE5 9RJ, UK;Institute of Immunology, Technical University Dresden, 01307, Dresden, Fetscherstraße 74, Germany;Children’s Hospital, Technical University Dresden, 01307, Dresden, Fetscherstraße 74, Germany

关键词: Inflammatory bowel disease;    Glycoprotein 2;    Gastroenterology;    Crohn’s disease;    Autoimmunity;    Autoantigen;    Autoantibody;   

Others  :  1121897
DOI  :  10.1186/1471-230X-12-102

 received in 2012-02-01, accepted in 2012-07-28,  发布年份 2012

【 摘 要 】

Background

Glycoprotein 2 (GP2) was discovered as the major autoantigen of Crohn’s disease (CD)-specific pancreatic autoantibodies (PAB). We investigated anti-GP2 IgA and IgG antibodies as novel serological parameters in CD and assessed their association with distinct disease phenotypes.

Methods

Anti-GP2 and anti-Saccharomyces cerevisiae (ASCA) IgA and IgG were detected by ELISA employing recombinant human GP2 and phosphopeptidomannan, respectively and PAB by indirect immunofluorescence (IIF) in 271 sera, 169 with CD and 102 with ulcerative colitis (UC). As healthy controls 160 adult blood donors and 65 children were included.

Results

Anti-GP2 IgG and/or IgA were more prevalent in CD (51/169, 30.2%) than in UC (9/102, 8.9%) patients and in controls (9/225, 4%) (p < 0.001 respectively). ASCA IgG and/or IgA were present in 60/169 (35.5%) in CD and in 7/102 (6.9%) in UC patients (p < 0.001). CD patients with ileocolonic location (L3) showed a significantly higher prevalence of anti-GP2 and ASCA IgA and/or IgG (40/113 and 48/113, respectively; p < 0.05 for both comparisons), whereas CD patients with colonic location (L2) revealed a significantly diminished prevalence for these autoantibody specificities (2/32 and 5/32, respectively, p < 0.05 for both). Anti-GP2 IgG were significantly more prevalent in CD patients with stricturing behaviour (B2) and perianal disease (7/11, p < 0.02) and less prevalent in those with penetrating behaviour (B3) and perianal disease (4/31, p < 0.05). The occurrence of anti-GP2 IgA and/or IgG was significantly more prevalent in CD patients with age at diagnosis of ≤16 years (16/31, p < 0.009). Prevalence of one or more anti-GP2 or ASCA IgA and/or IgG was significantly higher in L3, B2, and A1 and lower in L2 (68/113, 27/41, 23/31, 6/32; p < 0.04, respectively).

Conclusions

Anti-GP2 IgG and IgA, constituting novel CD specific autoantibodies, appear to be associated with distinct disease phenotypes identifying patients at a younger age, with ileocolonic location, and stricturing behaviour with perianal disease.

【 授权许可】

   
2012 Bogdanos et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

【 参考文献 】

• [1]Walker DG, Williams HR, Kane SP, Mawdsley JE, Arnold J, McNeil I, Thomas HJ, Teare JP, Hart AL, Pitcher MC, Walters JR, Marshall SE, Orchard TR: Differences in inflammatory bowel disease phenotype between South Asians and Northern Europeans living in North West London, UK. Am J Gastroenterol 2011, 106:1281-1289.
• [2]Bogdanos DP, Rigopoulou EI, Smyk DS, Roggenbuck D, Reinhold D, Forbes A, Laass MW, Conrad K: Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn’s disease specific-pancreatic autoantibodies. Autoimmun Rev 2011, 11:143-148.
• [3]Baumgart DC, Carding SR: Inflammatory bowel disease: cause and immunobiology. Lancet 2007, 369:1627-1640.
• [4]Logan I, Bowlus CL: The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 2010, 9:A372-A378.
• [5]Wehkamp J, Koslowski M, Wang G, Stange EF: Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn’s disease. Mucosal Immunol 2008, S1:67-74.
• [6]Roggenbuck D, Hausdorf G, Martinez-Gamboa L, Reinhold D, Büttner T, Jungblut PR, Porstmann T, Laass MW, Henker J, Büning C, Feist E, Conrad K: Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn’s disease. Gut 2009, 58:1620-1628.
• [7]Seibold F, Weber P, Jenss H, Wiedmann KH: Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn’s disease. Gut 1991, 32:1192-1197.
• [8]Stöcker W, Otte M, Ulrich S, Normann D, Finkbeiner H, Stöcker K, Jantschek G, Scriba PC: Autoimmunity to pancreatic juice in Crohn’s disease. Results of an autoantibody screening in patients with chronic inflammatory bowel disease. Scand J Gastroenterol Suppl 1987, 139:41-52.
• [9]LeBel D, Beattie M: The major protein of pancreatic zymogen granule membranes (GP-2) is anchored via covalent bonds to phosphatidylinositol. Biochem Biophys Res Commun 1988, 154:818-823.
• [10]Rindler MJ, Hoops TC: The pancreatic membrane protein GP-2 localizes specifically to secretory granules and is shed into the pancreatic juice as a protein aggregate. Eur J Cell Biol 1990, 53:154-163.
• [11]Hase K, Kawano K, Nochi T, Pontes GS, Fukuda S, Ebisawa M, Kadokura K, Tobe T, Fujimura Y, Kawano S, Yabashi A, Waguri S, Nakato G, Kimura S, Murakami T, Iimura M, Hamura K, Fukuoka S, Lowe AW, Itoh K, Kiyono H, Ohno H: Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature 2009, 462:226-230.
• [12]Hölzl MA, Hofer J, Kovarik JJ, Roggenbuck D, Reinhold D, Goihl A, Gärtner M, Steinberger P, Zlabinger GJ: The zymogen granule protein 2 (GP2) binds to scavenger receptor expressed on endothelial cells I (SREC-I). Cell Immunol 2011, 267:88-93.
• [13]Conrad K, Schmechta H, Klafki A, Lobeck G, Uhlig HH, Gerdi S, Henker J: Serological differentiation of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2002, 14:129-135.
• [14]Bossuyt X: Serologic markers in inflammatory bowel disease. Clin Chem 2006, 52:171-181.
• [15]Lakatos PL, Papp M, Rieder F: Serologic antiglycan antibodies in inflammatory bowel disease. Am J Gastroenterol 2011, 106:406-412.
• [16]Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman GL, Altstock RT, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S: New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007, 56:1394-1403.
• [17]Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, Obermeier F, Lopez R, Spector L, Fire E, Yarden J, Rogler G, Dotan N, Klebl F: Serum anti-glycan antibodies predict complicated Crohn’s disease behavior: a cohort study. Inflamm Bowel Dis 2010, 16:1367-1375.
• [18]Roggenbuck D, Reinhold D, Wex T, Goihl A, von Arnim U, Malfertheiner P, Büttner T, Porstmann T, Porstmann S, Liedvogel B, Bogdanos DP, Laass MW, Conrad K: Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn’s disease. Clin Chim Acta 2011, 412:718-724.
• [19]Roggenbuck D, Reinhold D, Wex T, von Arnim U, Malfertheiner P, Sturm A, Werner L, Bogdanos DP, Laass MW, Conrad K: Authors’ response: antibodies to GP2, the major zymogen granule membrane glycoprotein, are specific for Crohn’s disease and may reflect treatment response. Gut 2012, 61:164-165.
• [20]Pavlidis P, Forbes A, Bogdanos DP: Antibodies to glycoprotein 2 (GP2) in patients with inflammatory bowel diseases from UK. Clin Chim Acta 2011, 412:1163-1164.
• [21]Op De Beéck K, Vermeire S, Rutgeerts P, Bossuyt X: Antibodies to GP2, the major zymogen granule membrane glycoprotein, in inflammatory bowel diseases. Gut 2012, 61:162-164.
• [22]Lakatos PL, Altorjay I, Szamosi T, Palatka K, Vitalis Z, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Barta Z, Stocker W, Papp J, Veres G, Papp M: Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort. Inflamm Bowel Dis 2009, 15:365-374.
• [23]Seibold F, Mörk H, Tanza S, Müller A, Holzhüter C, Weber P, Scheurlen M: Pancreatic autoantibodies in Crohn’s disease: a family study. Gut 1997, 40:481-484.
• [24]Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl A):5-36.
• [25]IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition: Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr 2005, 41:1-7.
• [26]Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, Barakauskiene A, Villanacci V, Von Herbay A, Warren BF, Gasche C, Tilg H, Schreiber SW, Schölmerich J, Reinisch W: European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut 2006, 55(Suppl 1):i1-i15.
• [27]Wong SM, Lowe AW: Sequence of the cDNA encoding human GP-2, the major membrane protein in the secretory granule of the exocrine pancreas. Gene 1996, 171:311-312.
• [28]Zöphel K, Wunderlich G, Kotzerke J, von Landenberg P, Roggenbuck D: M22 based (manual) ELISA for TSH-receptor antibody (TRAb) measurement is more sensitive than 2nd generation TRAb assays. Clin Chim Acta 2009, 403:266.
• [29]Egerer K, Roggenbuck D, Hiemann R, Weyer MG, Büttner T, Radau B, Krause R, Lehmann B, Feist E, Burmester GR: Automated evaluation of autoantibodies on human epithelial-2 cells as an approach to standardize cell-based immunofluorescence tests. Arthritis Res Ther 2010, 12:R40. BioMed Central Full Text